Neuronal ceroid lipofuscinosis: Difference between revisions
CSV import |
CSV import |
||
| Line 33: | Line 33: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
== Neuronal_ceroid_lipofuscinosis == | |||
<gallery> | |||
File:Lipofuscin_neuro.jpg|Lipofuscin accumulation in neurons | |||
File:Mannose-6-phosphate.svg|Structure of Mannose-6-phosphate | |||
File:Flupirtine.svg|Chemical structure of Flupirtine | |||
</gallery> | |||
Revision as of 01:07, 18 February 2025
Neuronal ceroid lipofuscinosis (NCL) is a group of autosomal recessive neurodegenerative disorders, which are collectively classified under the broader category of lysosomal storage disease. The NCLs are characterized by the accumulation of a specific type of lipid-protein complex, known as lipofuscin, within the cells of the body, particularly the neurons.
Etiology
The NCLs are caused by mutations in various genes, which lead to the production of defective proteins. These proteins are involved in the normal functioning of the lysosome, a cellular organelle responsible for the breakdown and recycling of cellular waste products. The defective proteins result in the accumulation of lipofuscin within the lysosomes, leading to cell death and the clinical manifestations of the disease.
Clinical Features
The clinical features of the NCLs vary depending on the specific type of NCL, but generally include progressive neurological deterioration, seizures, visual impairment, and motor dysfunction. The onset of symptoms can occur at any age, from infancy to adulthood.
Diagnosis
The diagnosis of NCL is based on the clinical features, genetic testing, and the presence of characteristic autofluorescent lipofuscin deposits in tissue samples.
Treatment
There is currently no cure for the NCLs. Treatment is supportive and aimed at managing the symptoms of the disease.
Prognosis
The prognosis for individuals with NCL is generally poor, with most individuals dying within a few years of diagnosis.



